Amgen and Horizon have launched a return volley in their battle with the FTC, asking the U.S. District Court of Northern Illinois to deny the FTC’s July motion that sought to strike down arguments that Amgen and Horizon’s constitutional defenses are legitimate considerations in the case.
Source: Drug Industry Daily